Although the mechanism and long-term implications remain unclear, these studies affirm that the effect is occurring—and that a person’s prior HIV treatment regimen may play a role.
July 1, 2020: Quantifying bone fracture risks; real-world lipid effects of switching to TAF; pulmonary function impairment in MSM; immunomodulatory drugs and viral load blips.
When People Stop Newer HIV Meds, Time to Viral Rebound Not Better Than With Older Antiretroviral Therapy, NIH Study Finds
Researchers are trying to understand treatment interruptions as part of work to develop a future HIV cure and therapies that will not involve medications.
May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.
May 14, 2020: Recurring low-level viremia and morbidity/mortality risk; factors affecting severe bacterial infection in people with HIV; infective endocarditis cases on the rise; high rates of opioid use among U.S. veterans with HIV.
With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.
Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.
Whether lamivudine/dolutegravir is sufficient to achieve and maintain viral suppression was last year's question. As we move to 2020, a new question could be asked: Are three-drug regimens still necessary?
Taking more than five medications could be a problem. And many people with HIV are at risk of being on medication overload.
Timothy Ray Brown, known as "the Berlin patient," has begun taking PrEP to make sure he doesn't have to deal with an HIV diagnosis -- again.